|
|
 Previous Article | Table of Contents | Next Article 
Effects of injected leukemia inhibitory factor on hematopoietic and other
tissues in mice
D Metcalf, NA Nicola and DP Gearing
Walter and Eliza Hall Institute of Medical Research, Royal Melbourne
Hospital, Victoria, Australia.
Purified bacterially synthesized recombinant murine leukemia inhibitory
factor (LIF) was injected in varying doses for up to 2 weeks into adult
DBA/2 and C3H/HeJ mice. At high doses (2 micrograms, three times daily) LIF
exhibited toxic effects seen as behavioral changes, loss of body fat, and
thymus atrophy. Dose-related rises were observed in blood platelets,
erythrocyte sedimentation rates, and serum calcium to albumin ratios,
including dose schedules with no toxic effects. LIF induced a decrease in
bone marrow cell numbers, particularly in marrow lymphocytes, and a
moderate increase in spleen weight with a reduction in spleen lymphocytes
and an elevation of erythroid populations. LIF- injected mice showed a rise
in megakaryocytes up to twofold in the marrow and fivefold in the spleen,
with an associated 10-fold rise in megakaryocyte progenitor cells in the
spleen. Comparable rises in other types of progenitor cells were also
observed in the spleen. The observed changes indicate the biologic activity
of LIF in vivo and are consistent with the known wide range of in vitro
actions of this molecule. The ability of LIF to elevate megakaryocyte and
platelet levels suggests a potential clinical application of LIF in the
treatment of thrombocytopenias.
Volume 76,
Issue 1,
pp. 50-56,
07/01/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T.S.-C. Juan, B. Bolon, R. A. Lindberg, Y. Sun, G. Van, and F. A. Fletcher
Mice Overexpressing Murine Oncostatin M (OSM) Exhibit Changes in Hematopoietic and Other Organs that Are Distinct from Those of Mice Overexpressing Human OSM or Bovine OSM
Vet. Pathol.,
January 1, 2009;
46(1):
124 - 137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Jenkins, A. W. Roberts, C. J. Greenhill, M. Najdovska, T. Lundgren-May, L. Robb, D. Grail, and M. Ernst
Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis
Blood,
March 15, 2007;
109(6):
2380 - 2388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Masters, K. R. Palmer, W. S. Stevenson, D. Metcalf, E. M. Viney, N. S. Sprigg, W. S. Alexander, N. A. Nicola, and S. E. Nicholson
Genetic Deletion of Murine SPRY Domain-Containing SOCS Box Protein 2 (SSB-2) Results in Very Mild Thrombocytopenia
Mol. Cell. Biol.,
July 1, 2005;
25(13):
5639 - 5647.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tanaka, Y. Hirabayashi, T. Sekiguchi, T. Inoue, M. Katsuki, and A. Miyajima
Targeted disruption of oncostatin M receptor results in altered hematopoiesis
Blood,
November 1, 2003;
102(9):
3154 - 3162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Gunawardana, R. L. Basser, I. D. Davis, J. Cebon, P. Mitchell, C. Underhill, T. J. Kilpatrick, K. Reardon, M. D. Green, P. Bardy, et al.
A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer
Clin. Cancer Res.,
June 1, 2003;
9(6):
2056 - 2065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Mitchell, R. J. Swanson, and S. Oehninger
In Vivo Effect of Leukemia Inhibitory Factor (LIF) and an Anti-LIF Polyclonal Antibody on Murine Embryo and Fetal Development Following Exposure at the Time of Transcervical Blastocyst Transfer
Biol Reprod,
August 1, 2002;
67(2):
460 - 464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Sempowski, L. P. Hale, J. S. Sundy, J. M. Massey, R. A. Koup, D. C. Douek, D. D. Patel, and B. F. Haynes
Leukemia Inhibitory Factor, Oncostatin M, IL-6, and Stem Cell Factor mRNA Expression in Human Thymus Increases with Age and Is Associated with Thymic Atrophy
J. Immunol.,
February 15, 2000;
164(4):
2180 - 2187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Gainsford, H. Nandurkar, D. Metcalf, L. Robb, C. G. Begley, and W. S. Alexander
The residual megakaryocyte and platelet production in c-Mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor
Blood,
January 15, 2000;
95(2):
528 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. T. T. Sjin, K. A. Lord, A. Abdollahi, B. Hoffman, and D. A. Liebermann
Interleukin-6 and Leukemia Inhibitory Factor Induction of JunB Is Regulated by Distinct Cell Type-specific Cis-acting Elements
J. Biol. Chem.,
October 1, 1999;
274(40):
28697 - 28707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Senaldi, B. C. Varnum, U. Sarmiento, C. Starnes, J. Lile, S. Scully, J. Guo, G. Elliott, J. McNinch, C. L. Shaklee, et al.
Novel neurotrophin-1/B cell-stimulating factor-3: A cytokine of the IL-6 family
PNAS,
September 28, 1999;
96(20):
11458 - 11463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. P. Haines, R. B. Voyle, T. A. Pelton, R. Forrest, and P. D. Rathjen
Complex Conserved Organization of the Mammalian Leukemia Inhibitory Factor Gene: Regulated Expression of Intracellular and Extracellular Cytokines
J. Immunol.,
April 15, 1999;
162(8):
4637 - 4646.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Agnello, C. Meazza, C. G. Rowan, P. Villa, P. Ghezzi, and G. Senaldi
Leptin causes body weight loss in the absence of in vivo activities typical of cytokines of the IL-6 family
Am J Physiol Regulatory Integrative Comp Physiol,
September 1, 1998;
275(3):
R913 - R919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Gainsford, A. W. Roberts, S. Kimura, D. Metcalf, G. Dranoff, R. C. Mulligan, C. G. Begley, L. Robb, and W. S. Alexander
Cytokine Production and Function in c-mpl-Deficient Mice: No Physiologic Role for Interleukin-3 in Residual Megakaryocyte and Platelet Production
Blood,
April 15, 1998;
91(8):
2745 - 2752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Jenab and P. L. Morris
Testicular Leukemia Inhibitory Factor (LIF) and LIF Receptor Mediate Phosphorylation of Signal Transducers and Activators of Transcription (STAT)-3 and STAT-1 and Induce c-fos Transcription and Activator Protein-1 Activation in Rat Sertoli But Not Germ Cells
Endocrinology,
April 1, 1998;
139(4):
1883 - 1890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Stefanich, T. Senn, R. Widmer, C. Fratino, G.-A. Keller, and P. J. Fielder
Metabolism of Thrombopoietin (TPO) In Vivo: Determination of the Binding Dynamics for TPO in Mice
Blood,
June 1, 1997;
89(11):
4063 - 4070.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ware, M. Horowitz, B. Renshaw, J. Hunt, D Liggitt, S. Koblar, B. Gliniak, H. McKenna, T Papayannopoulou, B Thoma, et al.
Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death
Development,
January 5, 1995;
121(5):
1283 - 1299.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Pepper, N Ferrara, L Orci, and R Montesano
Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro
J. Cell Sci.,
January 1, 1995;
108(1):
73 - 83.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. H. Mitchell, R. J. Swanson, G. D. Hodgen, and S. Oehninger
Enhancement of In Vitro Murine Embryo Development by Recombinant Leukemia Inhibitory Factor
Reproductive Sciences,
July 1, 1994;
1(3):
215 - 219.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L Cheng, D. Gearing, L. White, D. Compton, K Schooley, and P. Donovan
Role of leukemia inhibitory factor and its receptor in mouse primordial germ cell growth
Development,
January 11, 1994;
120(11):
3145 - 3153.
[Abstract]
[PDF]
|
|
|
|
|
